'Lack of clarity' over new hospital plans
A review group set up to look at the plans, which the government approved last week, has highlighted "a lack of clarity and transparency about the decision-making" and "an absence of strategic healthcare, workforce and procurement planning".
The panel has made 34 key findings and 20 recommendations to tackle the issues raised as the business case for the project is developed.
Health Minister Tom Binet said he was confident they would "be able to address all the key findings and recommendations and assuage any public misgivings".
The review group said while the need for new healthcare facilities was urgent, more detail about decision making and costs would make the future phases of the project easier.
Talking about the business case for the new hospital, Deputy Jonathan Renouf said: "It is all very well wanting to 'get things done', but we need to know that what is being done is the right thing."
"This is the largest capital project the island has ever embarked on, and the panel has major concerns that there appears to be an ongoing lack of transparency which means that the Outline Business Case does not meet the expected standard to justify funding decisions of this scale."
Responding to the panel's concerns, the Health Minister, Deputy Tom Binet said: "The report is likely to cause a good deal of unnecessary concern.
"There is nothing...to suggest that progress towards the delivery of new healthcare facilities should be slowed and I am confident that the team will be able to address all the key findings and recommendations and assuage any public misgivings."
Follow BBC Jersey on X and Facebook. Send your story ideas to channel.islands@bbc.co.uk.
Major shake-up proposed for Jersey health services
Government of Jersey
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases. Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
Investment will support AstraZeneca's ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company's largest single investment in a facility to date WILMINGTON, Del., July 21, 2025--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Continuous manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials Our growing research and development investment in novel medicines Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US. Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here." Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth." Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines." Notes AstraZeneca in the US The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy. Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade. AstraZeneca AstraZeneca (Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca. View source version on Contacts Media Inquiries Fiona Cookson +1 212 814 3923Rachel Ross +1 202 427 1621 US Media Mailbox: usmediateam@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
3 days ago
- Forbes
Unlocking Workplace Productivity: Tackling The Hidden Challenges Behind ADHD And More
Ofer A. Lidsky is an entrepreneur with over 30 years of experience and is the founder and CEO of Excellent Brain. In today's demanding corporate landscape, productivity isn't just a metric—it's a mandate. Yet despite the growing availability of performance-enhancing tools, many teams still grapple with underperformance, disengagement and burnout. What's often overlooked is that productivity issues aren't always the result of poor work ethic; rather, they're often symptoms of deeper cognitive and organizational challenges such as ADHD. The Invisible Productivity Killers While time management and motivation are usually the go-to concerns in performance reviews, underlying factors like attention regulation, task switching fatigue and executive function limitations play a much larger role than most business leaders realize. For example, difficulties in sustaining focus, organizing tasks, and resisting distractions affect employees across all departments. These cognitive bottlenecks can stem from a variety of sources: chronic stress, digital overload, neurodivergent conditions such as ADHD or even poor sleep hygiene. Left unaddressed, they lead to delays, friction and a general decline in team effectiveness. Late Diagnoses, New Awareness One eye-opening development in the corporate world is the rise of late diagnoses of attention-related disorders in adults (ADHD)—especially among mid-career professionals. A growing number of parents are realizing they themselves show signs of ADHD only after their children are evaluated. This has created a wave of professionals rethinking their work patterns, stress responses and long-standing struggles with focus or organization. While this new awareness helps individuals better understand their limitations, it also places a responsibility on companies to adapt. Business leaders must ask: Are we giving our people the tools they need to work at their best? From The Top Down: Productivity Challenges For Leaders These challenges aren't limited to junior staff. Founders and executives can also display traits like rapid idea generation, impulsivity and high-energy decision-making. While this can fuel innovation, it can also result in burnout, inconsistent follow-through and poor strategic execution if not managed properly. Productivity, in this sense, is not about working more—it's about working smarter and in alignment with one's cognitive strengths. Strategies for Boosting Workplace Performance To improve focus and output across an organization, companies should consider a range of strategies, including: • Designing Distraction-Free Environments: Open-plan offices and constant digital pings kill deep work. Quiet zones, clear communication policies and digital hygiene training can go a long way. • Offering Flexible Task Management Systems: Not all brains operate well with rigid task structures. Allowing personalized planning tools or work styles increases accountability and ownership. • Providing Cognitive Wellness Tools: Just as physical wellness is supported by gyms and ergonomic furniture, mental performance can benefit from dedicated interventions like meditation apps, coaching or advanced cognitive training. • Investing In Neurotechnology-Based Solutions: Emerging tools like neurofeedback (i.e., real-time brain training based on EEG data) are gaining interest as non-invasive methods to enhance focus, regulate emotions, and build attention stamina over time. While still underutilized in the corporate world, some forward-thinking organizations are exploring these as part of their leadership development or employee wellness offerings. Creating a Culture That Supports Cognitive Diversity Ultimately, solving productivity challenges requires recognizing the diversity of cognitive styles within any workforce. That means moving beyond 'one-size-fits-all' time management advice and instead creating systems that honor different brain types, energy cycles and workflows. By embracing tools that promote self-awareness, emotional regulation, and cognitive alignment, organizations can unlock untapped potential—both in individuals and across teams. Final Thoughts Productivity is more than just output. It's a reflection of how well people are supported cognitively, emotionally and structurally. Leaders who acknowledge the hidden roadblocks—whether they're rooted in attention challenges, stress patterns or lack of fit between roles and thinking styles—will be best positioned to lead high-performing, resilient teams. As neuroscience and workplace psychology continue to converge, the future of productivity will belong to those who invest not just in their tools but in their people's minds. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
